Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response

DSpace/Manakin Repository

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response

Citable link to this page

 

 
Title: Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
Author: Zervantonakis, Ioannis K.; Iavarone, Claudia; Chen, Hsing-Yu; Selfors, Laura M.; Palakurthi, Sangeetha; Liu, Joyce F.; Drapkin, Ronny; Matulonis, Ursula; Leverson, Joel D.; Sampath, Deepak; Mills, Gordon B.; Brugge, Joan S.

Note: Order does not necessarily reflect citation order of authors.

Citation: Zervantonakis, I. K., C. Iavarone, H. Chen, L. M. Selfors, S. Palakurthi, J. F. Liu, R. Drapkin, et al. 2017. “Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.” Nature Communications 8 (1): 365. doi:10.1038/s41467-017-00263-7. http://dx.doi.org/10.1038/s41467-017-00263-7.
Full Text & Related Files:
Abstract: The lack of effective chemotherapies for high-grade serous ovarian cancers (HGS-OvCa) has motivated a search for alternative treatment strategies. Here, we present an unbiased systems-approach to interrogate a panel of 14 well-annotated HGS-OvCa patient-derived xenografts for sensitivity to PI3K and PI3K/mTOR inhibitors and uncover cell death vulnerabilities. Proteomic analysis reveals that PI3K/mTOR inhibition in HGS-OvCa patient-derived xenografts induces both pro-apoptotic and anti-apoptotic signaling responses that limit cell killing, but also primes cells for inhibitors of anti-apoptotic proteins. In-depth quantitative analysis of BCL-2 family proteins and other apoptotic regulators, together with computational modeling and selective anti-apoptotic protein inhibitors, uncovers new mechanistic details about apoptotic regulators that are predictive of drug sensitivity (BIM, caspase-3, BCL-XL) and resistance (MCL-1, XIAP). Our systems-approach presents a strategy for systematic analysis of the mechanisms that limit effective tumor cell killing and the identification of apoptotic vulnerabilities to overcome drug resistance in ovarian and other cancers.
Published Version: doi:10.1038/s41467-017-00263-7
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573720/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491986
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters